SystemOne Unveils Internal Analysis on Connectivity Across Seven Countries Revealing Transformative Results
Northampton, Mass, UNITED STATES, and Johannesburg, SOUTH AFRICA - August 8, 2023: SystemOne, a leader in data connectivity for global health, today announced the results of an internal analysis conducted on the impact of connectivity on diagnostic testing across seven diverse countries. The analysis revealed striking improvements in post-deployment testing efficiency and capacity, among many other benefits.
The analysis covered data from 7 countries and 6 independent papers and posters with pre- and post-connectivity periods ranging from 1 - 5 years prior to connectivity to 2 - 5 years post-implementation. Comparing these periods, the main outcomes included:
Increased testing efficiency, with the best-performing country adding 68 days of testing per year, and a 224% increase in the number of tests performed per module.
Improved resource management: The average number of tests performed per module per year, across 7 countries, increased by over 50%. SystemOne attributes the improvements to factors such as increased visibility into device up-time, adequate capacitation, better management of consumables, and targeted alert systems for inventory.
Enhanced performance: The average number of testing days per year across all 7 countries increased by more than 30 days.
Connectivity enabled reduced instrument downtime, proactive management of environmental and user issues, and preventive measures for stockouts, all of which contributed to this increase.
“This analysis underscores the transformative potential of connectivity to enable the promise of modern diagnostics,” said Chris Macek, CEO of SystemOne. “The results not only represent a leap in our collective quest to improve global health outcomes but also improvements in our ability to measure performance and value in diagnostics.”
|In the 4 top-performing countries of the 7 countries analyzed, which are countries that strongly utilized connectivity,
the number of tests per module increased even as the number of modules increased, showing better utilization of each instrument.
Within the analysis cohort, individual countries had varying results, which included (references available upon request):
Reduced time to patient initiation in care for MDR TB from 90 days down to 2 days;
Decreased median time from Xpert testing to RR TB treatment initiation from 35 days down to 10 days;
Increase in getting drug-resistant TB patients onto treatment, from 20% to 85%;
Reduction in national errors rates from 6.09% to 2.81%;
Shortened instrument maintenance turnaround time from 5.14 months to 2 weeks; and
Improved utilization rates from 28% to 75%.
Robust Return on Investment: The results of the analysis elucidate a significant improvement in Return on Investment (ROI) across the participating countries. By enhancing efficiency, reducing errors, and optimizing resource utilization, well-managed connectivity provides substantial cost savings and value generation.
"We've separately made numerous calculations to understand the costs and benefits of connectivity," said Brad Cunningham, COO, SystemOne. "We saw that the cost of connectivity ranges from 0.25% to 4% of the investment required for diagnostic devices and reagents, and provided a greater than 10x return in clinical and operational benefits."
SystemOne also conducted a similar analysis on 3 countries with connectivity systems available, but widely unused. While the data show that countries using the system well report higher returns, the corollary is also true: countries that do not use the system show little to no improvement in their clinical and operational performance.
For more information about the study and to explore opportunities to aggregate and interpret diagnostic connectivity data, please contact SystemOne.
Founded in Massachusetts in 2012, SystemOne focuses on producing solutions for disease surveillance and response. SystemOne has offices in Northampton, MA and Johannesburg, South Africa. The company’s new disease intelligence software, Aspect®, addresses numerous infectious diseases including Zika, Ebola, HIV, Malaria, Hepatitis C, TB, COVID-19, and more on a host of medical diagnostic devices.